Concepedia

Jeffrey T. Kuethe

JT

Statistics

Publications

65

Citations

3K

H-Index

33

Active since

1995

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

North Carolina State University

Emory University

Jeffrey T. Kuethe is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in chemistry, medicinal chemistry, and organic chemistry.

ORCID

Publications per year

1995–2025

65

Publications

65

Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes

Tesfaye Biftu, Ranabir SinhaRoy, Ping Chen et al. · Journal of Medicinal Chemistry · 2014 · 167 citations · Full text

, , +16

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

Thomas J. Tucker, Mark W. Embrey, Candice Alleyne et al. · Journal of Medicinal Chemistry · 2021 · 152 citations · Full text

, , +17

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Douglas G. Johns, Louis‐Charles Campeau, Puja Banka et al. · Circulation · 2023 · 141 citations · Full text

, , +17

A Practical, One-Pot Synthesis of Sulfonylated Pyridines

Kevin M. Maloney, Jeffrey T. Kuethe, Kathleen Linn · Organic Letters · 2010 · 137 citations

, , +5

The Reaction of α-Diazo-β-hydroxy Esters with Boron Trifluoride Etherate:  Generation and Rearrangement of Destabilized Vinyl Cations. A Detailed Experimental and Theoretical Study

Roberto Pellicciari, Benedetto Natalini, Bahman M. Sadeghpour et al. · Journal of the American Chemical Society · 1996 · 105 citations

, , +14

1–5 of 65